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who had undergone surgery for gastric non-cardia 
adenocarcinoma were included in the study. Five 
hundred and fifty-five (294 males, 261 females, mean 
age 57.3±4.1 years) patients consecutively admitted to 
the Emergency Care Unit served as control. Histological 
examination of tumor, lymph nodes and other tissues 
obtained at the t ime of surgery represented the 
diagnostic “gold standard”. An enzyme immunosorbent 
assay was used to detect serum anti-H pylori  (IgG) 
antibodies and Western blotting technique was utilized to 
search for anti-CagA protein (IgG). 
RESULTS: Two hundred and sixty-one of three hundred 
and seventeen (82.3%) GC patients and 314/555 (56.5%) 
controls were seropositive for anti-H pylori  (P<0.0001; 
OR, 3.58; 95%CI, 2.53-5.07). Out of the 317 cases, 267 
(84.2%) were seropositive for anti-CagA antibody vs 
100 out of 555 (18%) controls (P<0.0001; OR, 24.30; 
95%CI, 16.5-35.9). There was no difference between 
the frequency of H pylori  in intestinal type carcinoma 
(76.2%) and diffuse type cancer (78.8%). Intestinal 
metaplasia (IM) was more frequent but not signifi cant 
in the intestinal type cancer (83.4% vs 75.2% in diffuse 
type and 72.5% in mixed type). Among the patients 
examined for IM, 39.8% had IM type I, 8.3% type II and 
51.9% type Ⅲ (type Ⅲ vs others, P = 0.4).
C O N C L U S I O N :  T h i s s t u d y c o n f i r m s a h i g h 
seroprevalence of H pylori  infection in patients suffering 
from gastric adenocarcinoma and provides further 
evidence that searching for CagA status over H pylori 
infection might confer additional benefit in identifying 
populations at greater risk for this tumor. 
© 2005 The WJG Press and Elsevier Inc. All rights  reserved.
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Abstract
AIM: To investigate the seroprevalence of Helicobacter 
pylori (H pylori ) infection and its more virulent strains as 
well as the correlation with the histologic features among 
patients who had undergone surgery for gastric cancer 
(GC).
METHODS: Samples from 317 (184 males, 133 
females, mean age 69±3.4 years) consecutive patients 
INTRODUCTION
Gastric cancer (GC) is the world’s second leading cause 
of  cancer-related mortality[1] but in some countries it 
represents the most common malignancy in males[2].
   GC occurrence in many Italian regions is similar to that 
in Japan. In Italy, GC is usually discovered at a later stage 
and therapeutic approaches cannot save a majority of  
patients. As a consequence, mortality parallels incidence[3]. 
   T he mos t f r equent h i s to log i c t ype o f  GC i s 
adenocarcinoma, which is thought to originate from a 
continuing and active proliferation of  gastric pits following 
the destruction of  glands due to active inflammatory 
infiltration. The process that has been described by 
Correa[4] from an infl ammatory setting (gastritis) through 
intestinal metaplasia (IM) and dysplasia, evolves to 
adenocarcinoma. 
   In 1994, the International Agency for Research on 
Cancer defined H pylori as a class I gastric carcinogen[5]. 
Evidence supporting a causal association has been 
demonstrated by epidemiological data[6], ecologic studies[1] 
and in experimental animal models[7]. Regarding the fi rst 
aspect, in a prospective study including 1 526 Japanese 
subjects during a mean follow-up of  7.8 years (range 
1.0-10.6 years), 2.9% of  infected persons developed GC vs 
none among uninfected subjects[8]. A combined analysis of  
12 case-control studies (with 1 228 GC cases considered) 
nested within prospective cohorts has found an association 
between non-cardia GC and H pylori infection of  5.9 (95% 
confidence interval [CI] 3.4-10.3)[9]. A meta-analysis of  
21 case-control studies suggested that the risk of  GC is 
increased by threefold in those chronically infected with 
H pylori[10]. More recently, another meta-analysis of  case-
control studies with age- and sex-matched controls was 
published by Huang et al.[11]. In this work, a comprehensive 
literature search identified 16 qualified studies with 2 
284 cases and 2 770 controls. The authors found that 
H pylori and CagA (cytotoxin-associated gene A) protein 
seropositivity signifi cantly increases the risk for GC by 2.28- 
and 2.87-fold, respectively. 
    There is stil l no final conclusion regarding the 
association between the infection and the malignancy due 
to marked geographic variations. Some studies have not 
found any correlation between seropositivity for H pylori 
antibodies (as an indicator of  H pylori infection) and GC[12-14]. 
For example, in the study performed by Rudi et al.[12] in 
Germany, 58.6% of  patients suffering from GC and 50.6% 
of  control subjects have IgG antibodies against H pylori. 
In Gambia, though more virulent strains of  H pylori are 
present, gastric atrophy and IM are rare[15]. Seropositivity 
for H pylori and the CagA antigen cannot explain the 
differences in the prevalence of  precancerous gastric 
lesions in two Chinese populations with contrasting GC 
rates[16]. Recently, Wong et al.[17] found that the incidence in 
GC development is similar between the subjects receiving 
H pylori eradication treatment and those receiving placebo 
during a period of  7.5 years in a high-risk region of  China. 
Furthermore, not all the stomach tumors are H pylori 
positive. 
   In previous local pilot studies in North Italy, a high 
prevalence of  H pylori infection has been associated to the 
presence of  GC[18,19]. To investigate the correlation in a 
vast area of  Northwest Italy in more detail, we started a 
research network on gastric cancer and precursor lesions 
in 1993, which we named Metaplasia H pylori Histology 
(MHEPHISTO). In this multicenter survey, a prospective 
case-control study of  patients who had undergone surgery 
for GC in Northwestern Italy was performed. The aim was 
to ascertain the seroprevalence of  H pylori infection and its 
more virulent strains by searching for antibodies against 
the CagA protein and to establish the correlation with the 
subtypes of  IM. 
MATERIALS AND METHODS
Study population
Specimens from 317 (184 males, 133 females, mean age 
69±3.4 years) consecutive patients who had undergone 
surgery for gastric non-cardia adenocarcinoma were 
included in the study. Five hundred and fi fty-fi ve patients 
(294 males, 261 females) consecutively admitted to the 
Emergency Care Unit of  S. Giovanni Battista (Molinette) 
Hospital of  Torino served as control with a mean age 57.3
±4.1 years. Cases and controls came from the geographical 
area of  Northwestern Italy.
Methods
Clinical diagnosis of  malignancy was established by 
standard medical examinations including upper GI 
endoscopy, d iagnost ic u l trasound and computed 
tomography (CT) scan. Endoscopic ultrasound (EUS) 
served as a part of  the routine examination.
   Histological examination of  tumor, lymph nodes and 
other tissues obtained at the time of  surgery represented 
the diagnostic “gold standard”. Pathologists with special 
interest and experience in GI pathology reviewed the 
histological sections. Appropriate forms were used to 
record the pathological fi ndings. All the diagnostic criteria 
used for our survey were discussed and sample slides were 
reviewed by the pathologists before the study to minimize 
interobserver variations as far as possible. 
Surgical specimens were immersed in paraffin for 
routine pathological examination. Microtome sections 
(7-8 μm thick) were stained with hematoxylin and eosin as 
well as high iron diamine/alcian blue to identify sialo-and 
sulfomucins. Adenocarcinoma was diagnosed when the 
malignant cells invaded the lamina propria in single cells, 
glandular or solid nest arrangements, usually accompanied 
with fi brosis of  the surrounding tissue. Carcinomas were 
classifi ed histologically as either intestinal or diffuse type 
in accordance with Lauren’s classification[20]. Intestinal 
metaplasia classifi ed according to Filipe et al.[21] was defi ned 
as metaplastic transformation of  gastric glandular and 
surface epithelium towards intestinal mucosal elements 
including goblet, absorptive, and Paneth cells. 
Personnel not aware of  the histological diagnoses 
performed serological testing. A commercial enzyme 
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immunosorbent assay (ELISA, Helori-test® Eurospi-
tal, Trieste, Italy) was used to detect serum anti-H pylori 
(IgG) antibodies. The assay sensitivity and specifi city were 
94% and 87%[22]. Briefly, calibrators, positive and nega-
tive controls and diluted (1:200) serum samples were 
added to the wells coated with purified H pylori group-
specific antigens. Plates were incubated for 60 min at 
37 ℃, and then the liquid was removed completely and 
washed thrice with 200 μL/well of  washing solution. One 
hundred microliters of  anti-IgG conjugate was pipetted 
into each well. The wells were incubated for 60 min at 37 
℃, washed thrice with 200 μL/well of  washing solution 
and 100 μL of  chromogenic substrate was added to each 
well. The wells were again incubated for 30 min at 37 ℃, 
the reaction was stopped by adding 25 μL of  the stop-
ping solution. Reading was performed at 405 nm and the 
mean optical density was expressed as a percentage of  the 
optical density of  positive control serum assayed on the 
same plate. To detect the presence of  serum IgG against
H pylori CagA protein, Western blotting technique was 
used. H pylori CCUG 17874 (type strain, CagA positive, 
CagA mass = 128 ku) was cultured in Brucella broth con-
taining 0.2% cyclodextrin at 37 ℃ in a microaerobic en-
vironment for 48 h. At the end of  incubation, to exclude 
the presence of  contaminants, the broth culture was sub-
cultured onto plain blood agar plates and examined under 
optical microscope after staining with carbol fuchsin. The 
broth culture was centrifuged and the pellet was washed 
twice with phosphate buffered saline (PBS, pH 7.4) at 4 
℃. A whole cell suspension containing approximately 1010 
bacteria was lysed and denatured in Laemmli buffer at 95 
℃ for 5 min, then run electrophoretically on 10% poly-
acrylamide gel with sodium dodecyl sulfate. Proteins were 
transferred onto nitrocellulose sheets saturated with 3% 
defatted milk in PBS with 0.1% Triton X (PBSMT). Strips 
were cut and serum samples were assayed at the dilution 
of  1:100 in PBSMT. After overnight incubation with con-
stant agitation at room temperature, strips were washed 
with PBSMT and then incubated with an anti-human IgG 
serum conjugated with peroxidase at room temperature 
for 90 min. After the washings, the reaction was visualized 
by adding the substrate (H2O2 in a solution of  4-chloro-
1-naphthol in Tris buffer 0.05 mol/L, pH 6.8). We used 
serum samples from patients infected respectively with 
CagA positive and negative H pylori strains as positive and 
negative controls with or without antibodies to CagA. Spe-
cifi c polyclonal antisera against CagA (kindly donated by 
Biocine-Chiron, Siena) was used as further controls.
The seroprevalence of  anti-H pylori as well as the 
distribution of  anti-CagA seropositivity in cases and 
controls were compared using the χ2 test. Odds ratio 
(OR) and 95%CI assessing the risk of  GC associated with 
H pylori infection were calculated using the Mantel-
Haenszel method. P<0.05 was considered statistically 
signifi cant.
RESULTS
All patients selected were suffering from gastric non-cardia 
adenocarcinoma (intestinal type in 181, diffuse type in 85 
and mixed type in 51). Among these, 261 out of  317 (82.3%) 
were seropositive for IgG anti-H pylori compared to 314 
out of  555 (56.5%) controls (P<0.0001; OR, 3.58; 95%CI, 
2.53-5.07) (Table 1). Moreover, out of  the 317 cases, 267 
(84.2%) were seropositive for anti-CagA antibody vs 100 
out of  555 (18%) controls (P<0.0001; OR, 24.30; 95%CI, 
16.5-35.9) (Table 1). 
   There was no difference between the frequency of  
H pylori in intestinal type and diffuse type carcinoma. 
Overall, H pylori occurred in 138 out of  181 patients 
(76.2%) suffering from the former compared to 67 out 
of  85 (78.8%) suffering from the latter (P = NS) (Table 
2). Intestinal metaplasia was more frequently seen in the 
intestinal type cancer (151/181, 83.4% vs 64/85, 75.2% 
in diffuse type and 37/51, 72.5% in mixed type) but the 
difference was not statistically signifi cant (P = NS, Table 
2). Among the patients examined for IM, 72 out of  181 
(39.8%) had IM type I, 15 out of  181 (8.3%) type II, and 
94 out of  181 (51.9%) type III, (type III vs others P = 0.4). 
Furthermore, among the patients with IM of  either body 
or antral mucosa, 117 out of  151 (77.4%) with intestinal 
type carcinoma were positive for H pylori compared to 59 
out of  85 (69.4%) with diffuse type carcinoma (P = 0.17). 
DISCUSSION
Gastric carcinogenesis involves a slow but continuous 
stepwise evolution from superfi cial gastritis and glandular 
atrophy to metaplasia and dysplasia and finally to 
adenocarcinoma[23]. The process of  carcinogenesis which 
may well extend over decades provides an excellent 
opportunity for early detection and intervention to prevent 
further progression of  the sequence of  events preceding 
the development of  the neoplasma. This is especially true 
because H pylori (which can be readily treated) is known to 
be the main factor though not the only[24] etiological agent 
Table 1  Seroprevalence of anti-H pylori antibodies among patients 
with gastric cancer  and controls
 
           Parameters              Gastric cancer                     Controls              
     (%)                                  (%)
      H pylori positive    261                                  314
                                            (82.3)                              (56.5)            
      H pylori negative     56                                   241
    Anti-CagA positive    267                                  100
                       (84.2)                                (18)
    Anti-CagA negative     50                                   455
Table 2 Features of patients suffering from gastric cancer based on 
tumor subtype
 
 Parameters                    Intestinal type carcinoma        Diffuse type carcinoma  
                  (%)        (%)
 H pylori positive        138/181 (76.2%)                    67/85 (78.8%)
 Intestinal metaplasia          151/181 (83.4%)                    64/85 (75.2%)
and initiating carcinogen. 
   On the other hand, the prognosis of  GC is poor. In 
most industrialized countries, only around 10% subjects 
survive for 5 years. The sole exception is Japan where 
this malignancy is often identified at an early stage and 
in younger and fi tter patients[26]. In Italy, 10-year survival 
is 12.1% in all GC patients and 20.8% in resected cases. 
However, though the survival is good when the diagnosis 
is performed at an early stage, only a few cases are 
diagnosed at stages when cure by radical surgery is more 
probable[3].
   Regarding the biological plausibility for a causal role, a 
higher intragastric pH after the development of  atrophic 
gastritis provoked by H pylori may favor the production of  
carcinogens[26]. The generation of  reactive oxygen species 
and increased level of  inducible nitric oxide synthase 
may in turn cause genetic alterations leading to cancer[27]. 
Nardone et al.[28] demonstrated by morphometric and 
immunohistochemical techniques that H pylori infection 
seems to be responsible for genomic instability in patients 
with chronic atrophic gastritis and eradication of  H 
pylori can reverse inflammation, atrophy, metaplasia, and 
genomic instability.  
   CagA gene is situated at the end of  the large region 
of  the genome identified to be a pathogenicity island 
(PAI). The strains of  H pylori expressing CagA protein are 
considered more virulent, being linked with an increased 
risk of  duodenal ulcer and GC[23]. Moreover, CagA status 
is associated with a higher prevalence of  p53 mutation in 
gastric adenocarcinoma[29].  
   This multicenter study showed a signifi cant association 
between H pylori infection in particular by its more virulent 
strains and the presence of  GC. In addition, the results 
confi rmed that type III IM was most frequently associated 
with H pylori infection. These data suggest that CagA status 
is a helpful parameter in defi ning a subgroup of  H pylori-
infected patients at increased risk of  developing gastric 
adenocarcinoma. The difference between the rate of  H 
pylori infection and more virulent strains can be explained 
by the fact that CagA antibodies persist for a longer time 
than H pylori IgG surface antibodies. Hence, relying on H 
pylori IgG antibodies alone might misclassify a signifi cant 
proportion of  patients who once had the infection[11].
   The established epidemiological association does not 
prove that there is a direct causal relationship. Therefore, 
to further confi rm a causal role, we are going to evaluate 
the effect of  H pylori on the morphological changes of  
gastric mucosa in patients with precancerous gastric 
lesions. 
   In conclusion, seroprevalence of  H pylori infection is 
high in patients suffering from gastric adenocarcinoma, 
which provides further evidence that searching for CagA 
status over H pylori infection might confer additional 
benefi t for identifying populations at greater risk for this 
tumor. 
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